List of chemotherapy regimens: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
mNo edit summary
Line 8: Line 8:


==List of Chemotherapy Regimens==
==List of Chemotherapy Regimens==
{| class="wikitable"
 
! Name !! Components !! Example of uses, and other notes
|-
| '''[[7+3 regimen|7+3]]'''
| 7 days of Ara-C ([[cytarabine]]) plus 3 days of an [[anthracycline]] [[antibiotic]], either [[daunorubicin]] ([[DA regimen|DA]] or [[DAC regimen|DAC]] variant) or [[idarubicin]] ([[IA regimen|IA]] or [[IAC regimen|IAC]] variant)
| [[Acute myelogenous leukemia]], excluding [[acute promyelocytic leukemia]]
|-
| '''[[ABVD]]''' <ref name="pmid54209">{{cite journal |author=Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C |title=Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP |journal=Cancer |volume=36 |issue=1 |pages=252–9 |year=1975 |month=July |pmid=54209 |doi= |url=}}</ref>
| [[Adriamycin]], [[bleomycin]], [[vinblastine]], [[dacarbazine]]
| [[Hodgkin's lymphoma]]
|-
| '''AC'''
| [[Adriamycin]]/[[Doxorubicin]], [[Cyclophosphamide]]
| [[Breast cancer]]
|-
| '''[[ACVBP-R regimen|ACVBP-R]]'''
|  [[Adriamycin]], [[Cytoxan]], [[Vindesine]], [[Bleomycin]], [[Prednisone]], [[Rituximab]]
| [[Diffuse large B-cell lymphoma]]
|-
| '''ADOC''' <ref name="pmid10555755">{{cite journal |author=Berruti A, Borasio P, Gerbino A, ''et al.'' |title=Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience |journal=Br. J. Cancer |volume=81 |issue=5 |pages=841–5 |year=1999 |month=November |pmid=10555755 |pmc=2374302 |doi=10.1038/sj.bjc.6690773 |url=}}</ref>
| [[Doxorubicin]], [[cisplatin]], [[vincristine]], [[cyclophosphamide]]
| [[Thymic carcinoma]]
|-
| '''BACOD'''
| [[Bleomycin]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[vincristine]] (Oncovin), [[dexamethasone]]
| [[Non-Hodgkin's lymphoma]]
|-
| '''[[BEACOPP]]''' <ref name="pmid9850026">{{cite journal |author=Diehl V, Franklin J, Hasenclever D, ''et al.'' |title=BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group |journal=J. Clin. Oncol. |volume=16 |issue=12 |pages=3810–21 |year=1998 |month=December |pmid=9850026 |doi= |url=}}</ref>
| [[Bleomycin]], [[etoposide]], [[Adriamycin]] ([[doxorubicin]]), [[cyclophosphamide]], [[Oncovin]] ([[vincristine]]), [[procarbazine]], [[prednisone]]
| [[Hodgkin's lymphoma]]
|-
| '''BEP'''
| [[Bleomycin]], [[etoposide]], platinum ([[cisplatin]])
| [[Testicular cancer]], [[germ cell tumor]]s
|-
| '''CA'''
| [[cyclophosphamide]], [[doxorubicin]] (Adriamycin) (same as AC)
| [[Breast cancer]]
|-
| '''CAF'''
| [[Cyclophosphamide]], [[Adriamycin]]/[[Doxorubicin]], [[5-FU]]/[[Fluorouracil]]
| [[Breast cancer]]
|-
| '''CAPOX'''
| [[Capecitabine]] and [[oxaliplatin]]
| [[Colorectal cancer]]
|-
| '''CAV'''
| [[Cyclophosphamide]], [[Adriamycin]]/[[Doxorubicin]], [[Vincristine]]
| [[Lung cancer]]
|-
| '''CBV'''
| [[Cyclophosphamide]], [[BCNU|BCNU (carmustine)]], VP-16 ([[etoposide]])
| [[Lymphoma]]
|-
| '''CEOP-R'''
| [[Cyclophosphamide]], [[etoposide]], vincristine ([[Oncovin]]), [[prednisone]] + rituximab
| [[Diffuse large B-cell lymphoma]] when patient cannot be given an anthracycline 
|-
| '''CEPP'''
| [[Cyclophosphamide]], [[etoposide]], [[procarbazine]], [[prednisone]]
| [[Non-Hodgkin's lymphoma]]
|-
| '''ChlVPP/EVA'''
| [[Chlorambucil]], [[vincristine]] (Oncovin), [[procarbazine]], [[prednisone]], [[etoposide]], [[vinblastine]], [[doxorubicin]] (Adriamycin)
| [[Hodgkin's lymphoma]]
|-
| '''CHOEP'''
| [[Cyclophosphamide]], hydroxydaunorubicin ([[doxorubicin]]), [[etoposide]], vincristine ([[Oncovin]]), [[prednisone]]
| [[Non-Hodgkin's lymphoma]]
|-
| '''[[CHOP]]'''
| [[Cyclophosphamide]], [[doxorubicin]] ([[hydroxydoxorubicin]]), vincristine ([[Oncovin]]), [[prednisone]]
| [[Non-Hodgkin's lymphoma]]
|-
| '''CHOP-R''' or '''R-CHOP'''
| CHOP + [[rituximab]]
| [[B cell]] [[non-Hodgkin lymphoma]]
|-
| '''[[CHOP|COP]]''' or '''[[CHOP|CVP]]'''
| [[Cyclophosphamide]], [[vincristine]] (Oncovin), and [[prednisone]]
| Non-Hodgkin lymphoma in patients with history of [[cardiovascular disease]]
|-
| '''ClaPD'''
| [[Clarithromycin]], [[pomalidomide]], [[dexamethasone]]
| [[Multiple myeloma]]
|-
| '''[[CMF (therapy)|CMF]]'''
| [[Cyclophosphamide]], [[Methotrexate]], and [[5-Fluorouracil]]
| [[Breast Cancer]]
|-
| '''CMV'''
| [[Cisplatin]], [[methotrexate]], [[vinblastine]]
| Metastatic [[transitional cell carcinoma]] of the urinary tract
|-
| '''CODOX-M/IVAC''' <ref name="pmid12181251">{{cite journal |author=Mead GM, Sydes MR, Walewski J, ''et al.'' |title=An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study |journal=Ann. Oncol. |volume=13 |issue=8 |pages=1264–74 |year=2002 |month=August |pmid=12181251 |doi= |url=}}</ref>
| Cyclophosphamide, vincristine, doxorubicin, methotrexate (CODOX-M) + ifosfamide, etopiside (VP-16), cytarabine (Ara-C) (IVAC)
| [[Burkitt's lymphoma]]
|-
| '''[[COPP]]'''
| [[Cyclophosphamide]], Oncovin (vincristine), [[procarbazine]] and prednisone
| [[Non-Hodgkin lymphoma]]
|-
| '''CT''' or '''TC'''
| [[Cyclophosphamide]] and [[docetaxel]] (Taxotere)
| [[Breast cancer]]
|-
| '''CTD'''
| [[Cyclophosphamide]], [[thalidomide]], [[dexamethasone]]
| [[AL amyloidosis]]
|-
| '''CVAD'''
| [[Cyclophosphamide]], [[vincristine]], [[doxorubicin]] (Adriamycin), [[dexamethasone]]
| Aggressive [[non-Hodgkin lymphoma]], [[lymphoblastic lymphoma]], some forms of [[leukemia]]
|-
| '''CyBorD'''
| [[Cyclophosphamide]], [[bortezomib]], [[dexamethasone]]
| [[Multiple myeloma]], [[AL amyloidosis]]
|-
| '''DA-EPOCH''' <ref name="pmid11929754">{{cite journal |author=Wilson WH, Grossbard ML, Pittaluga S, ''et al.'' |title=Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy |journal=Blood |volume=99 |issue=8 |pages=2685–93 |year=2002 |month=April |pmid=11929754 |doi= |url=}}</ref>
| Dose-adjusted [[Etopiside]], [[prednisone]], [[vincristine]] (Oncovin), [[Cyclophosphamide]] and doxorubicin
| Newly diagnosed, aggressive [[non-Hodgkin lymphoma]]
|-
| '''DCEP'''
| [[Dexamethasone]], [[cyclophosphamide]], [[etoposide]], [[platinum-based antineoplastic|platinum agent]]
| [[Multiple myeloma]]
|-
| '''DHAP''' <ref name="pmid3334893">{{cite journal |author=Velasquez WS, Cabanillas F, Salvador P, ''et al.'' |title=Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) |journal=Blood |volume=71 |issue=1 |pages=117–22 |year=1988 |month=January |pmid=3334893 |doi= |url=}}</ref>
| Dexamethasone, cytarabine (high-dose ARA-C), cisplatin
| Recurrent or refractory [[non-Hodgkin lymphoma]]
|-
| '''DHAX-R''' <ref name="pmid20709662">{{cite journal |author=Lignon J, Sibon D, Madelaine I, ''et al.'' |title=Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma |journal=Clin Lymphoma Myeloma Leuk |volume=10 |issue=4 |pages=262–9 |year=2010 |month=August |pmid=20709662 |doi=10.3816/CLML.2010.n.055 |url=}}</ref>
| Dexamethasone, cytarabine, oxaliplatin and rituximab
| Relapsed or refractory B-cell [[non-Hodgkin lymphoma]]
|-
| '''DICE'''
| [[Dexamethasone]], [[ifosfamide]], [[cisplatin]], [[etoposide]] (VP-16)
| Aggressive relapsed [[lymphomas]], progressive [[neuroblastoma]]
|-
| '''DT-PACE'''
| [[Dexamethasone]], [[thalidomide]], [[platinum-based antineoplastic|platinum agent]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]]
| [[Multiple myeloma]]
|-
| '''EC'''
| [[Epirubicin]], [[Cyclophosphamide]]
| [[Breast cancer]]
|-
| '''ECF'''
| [[Epirubicin]], [[cisplatin]], [[fluorouracil]]
| [[Gastric cancer]] and [[oesophageal cancer]]
|-
| '''EOX'''
| [[Epirubicin]], [[oxaliplatin]], [[capecitabine]]
| [[Esophageal cancer]], [[gastric cancer]]
|-
| '''EP'''
| [[Etoposide]], [[platinum-based antineoplastic|platinum agent]]
| [[testicular cancer]], [[germ cell tumor]]s
|-
| '''EPOCH'''
| [[Etoposide]], [[prednisone]], [[vincristine]] (Oncovin), [[cyclophosphamide]], and [[hydroxydaunorubicin]]
| [[Non-Hodgkin lymphoma]]s
|-
| '''EPOCH-R''' or '''R-EPOCH'''
| [[Etoposide]], [[prednisone]], [[vincristine]] (Oncovin), [[cyclophosphamide]], and [[hydroxydaunorubicin]] plus [[rituximab]]
| [[B cell]] [[Non-Hodgkin lymphoma]]s
|-
| '''ESHAP'''
| [[Etopiside]], methylprednisolone (Solu-medrol), cytarabine (ARA-C), cisplatin
| Relapsed or refractory [[non-Hodgkin lymphoma]]
|-
| '''ESHAP-R''' or '''R-ESHAP'''
| [[etoposide]], [[methylprednisolone]] (a [[steroid hormone]]), [[cytarabine]] (ara-C), [[platinum-based antineoplastic|platinum agent]] plus [[rituximab]]
| [[Non-Hodgkin lymphoma]]
|-
| '''FAM'''
| [[Fluorouracil]], [[doxorubicin]] (Adriamycin), [[mitomycin]]
| Metastatic small bowel adenocarcinoma
|-
| '''FCM''' or '''FMC'''
| [[Fludarabine]], [[cyclophosphamide]], [[mitoxantrone]]
| [[B cell]] non-Hodgkin lymphoma
|-
| '''FCM-R''' or '''R-FCM''' or '''R-FMC''' or '''FMC-R'''
| [[Fludarabine]], [[cyclophosphamide]], [[mitoxantrone]] plus [[rituximab]]
| [[B cell]] non-Hodgkin lymphoma
|-
| '''FM'''
| [[Fludarabine]], [[mitoxantrone]]
| [[B cell]] non-Hodgkin lymphoma
|-
| '''FMR'''
| [[Fludarabine]], [[mitoxantrone]], and [[rituximab]]
| [[B cell]] non-Hodgkin lymphoma
|-
| '''FEC'''
| [[Fluorouracil]] (5-FU), [[epirubicin]], [[cyclophosphamide]]
| [[Breast cancer]]
|-
| '''FL'''
| [[Fluorouracil]] (5-FU), leucovorin ([[folinic acid]])
| [[Colorectal cancer]]
|-
| '''FLAG'''
| [[Fludarabine]], [[cytarabine]], [[G-CSF]]
| Relapsed or [refractory [[acute myelogenous leukemia]]
|-
| '''FLAG-Ida''' or '''FLAG-IDA''' or '''IDA-FLAG''' or '''Ida-FLAG'''
| [[Fludarabine]], [[cytarabine]], [[idarubicin]], [[G-CSF]]
| Relapsed or [[refractoriness|refractory]] [[acute myelogenous leukemia]]
|-
| '''FLAG-Mito''' or '''FLAG-MITO''' or '''Mito-FLAG''' or '''MITO-FLAG''' or '''FLAMG'''
| [[Mitoxantrone]], [[fludarabine]], [[cytarabine]], [[G-CSF]]
| Relapsed or refractory [[acute myelogenous leukemia]]
|-
| '''FLAMSA'''
| [[Fludarabine]], [[cytarabine]], [[amsacrine]]
| [[Myelodysplastic syndrome]], [[acute myeloid leukemia]]
|-
| '''FLAMSA-BU''' or '''FLAMSA-Bu'''
| [[Fludarabine]], [[cytarabine]], [[amsacrine]], [[busulfan]]
| [[Myelodysplastic syndrome]], [[acute myeloid leukemia]]
|-
| '''FLAMSA-MEL''' or '''FLAMSA-Mel'''
| [[Fludarabine]], [[cytarabine]], [[amsacrine]], [[melphalan]]
| [[Myelodysplastic syndrome]], [[acute myeloid leukemia]]
|-
| '''FN-D''' <ref name="pmid8648382">{{cite journal |author=McLaughlin P, Hagemeister FB, Romaguera JE, ''et al.'' |title=Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma |journal=J. Clin. Oncol. |volume=14 |issue=4 |pages=1262–8 |year=1996 |month=April |pmid=8648382 |doi= |url=}}</ref>
| Fludarabine, mitoxantrone (Novantrone), dexamethasone
| Recurrent or refractory indolent [[non-Hodgkin lymphoma]]
|-
| '''FOLFIRI''' <ref name="pmid10744089">{{cite journal |author=Douillard JY, Cunningham D, Roth AD, ''et al.'' |title=Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial |journal=Lancet |volume=355 |issue=9209 |pages=1041–7 |year=2000 |month=March |pmid=10744089 |doi= |url=}}</ref>
| Leucovorin, infusional fluorouracil, irinotecan
| Metastatic [[colorectal cancer]]
|-
| '''FOLFIRINOX'''
| [[Fluorouracil]] (5-FU), leucovorin ([[folinic acid]]), [[irinotecan]], [[oxaliplatin]]
| [[Pancreatic cancer]]
|-
| '''[[FOLFOX]]'''
| [[Fluorouracil]], [[leucovorin]] ([[folinic acid]]), and [[oxaliplatin]]
| [[Colorectal cancer]]
|-
| '''GVD'''
| [[Gemcitabine]], [[vinorelbine]], pegylated liposomal [[doxorubicin]]
| [[Hodgkin lymphoma]]
|-
| '''GemOx'''
| [[Gemcitabine]], [[oxaliplatin]]
| [[Non-Hodgkin's lymphoma]]
|-
| '''GemOx-R'''
| [[Gemcitabine]], [[oxaliplatin]], [[rituximab]]
| [[Non-Hodgkin lymphoma]]s
|-
| '''HYPER-CVAD''' <ref name="pmid10561310">{{cite journal |author=Thomas DA, Cortes J, O'Brien S, ''et al.'' |title=Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia |journal=J. Clin. Oncol. |volume=17 |issue=8 |pages=2461–70 |year=1999 |month=August |pmid=10561310 |doi= |url=}}</ref>
| Hyperfractionated cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin), dexamethasone ([[Decadron]])
| [[Burkitt's lymphoma]]
|-
| '''IA''' or '''IAC'''
| [[Idarubicin]] x 3 days plus Ara-C ([[cytarabine]]) x 7 days, a variant of classical [[7+3 regimen|7+3]] regimen
| [[Acute myelogenous leukemia]], excluding [[acute promyelocytic leukemia]]
|-
| '''ICE''' <ref name="pmid10577849">{{cite journal |author=Moskowitz CH, Bertino JR, Glassman JR, ''et al.'' |title=Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma |journal=J. Clin. Oncol. |volume=17 |issue=12 |pages=3776–85 |year=1999 |month=December |pmid=10577849 |doi= |url=}}</ref>'
| Ifosfamide, carboplatin, etopiside
| Relapsed or primary refractory [[non-Hodgkin lymphoma]]
|-
| '''ICE-R'''
| ICE + [[rituximab]]
| Relapsed or primary refractory [[non-Hodgkin lymphoma]]
|-
| '''IFL''' <ref name="pmid11006366">{{cite journal |author=Saltz LB, Cox JV, Blanke C, ''et al.'' |title=Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group |journal=N. Engl. J. Med. |volume=343 |issue=13 |pages=905–14 |year=2000 |month=September |pmid=11006366 |doi= |url=}}</ref>
| [[Irinotecan]], [[bolus fluorouracil]] and leucovorin
| Metastatic [[Colorectal cancer|colorectal cancer]]
|-
| '''m-BACOD'''
| [[Methotrexate]], [[bleomycin]], doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone ([[Decadron]])
| [[Non-Hodgkin lymphoma]]
|-
| '''MACOP-B''' <ref name="pmid2580468">{{cite journal |author=Klimo P, Connors JM |title=MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma |journal=Ann. Intern. Med. |volume=102 |issue=5 |pages=596–602 |year=1985 |month=May |pmid=2580468 |doi= |url=}}</ref>
| [[Methotrexate]], [[leucovorin]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[vincristine]] (Oncovin), [[prednisone]], [[bleomycin]]
| Non-Hodgkin lymphoma
|-
| '''MINE'''
| [[Mesna]], [[ifosfamide]], [[novantrone]], [[etoposide]]
| [[Non-Hodgkin's lymphoma]] and [[Hodgkin lymphoma]] in [[relapse]] or [[refractoriness|refractory]] cases
|-
| '''MINE-R''' or '''R-MINE'''
| [[Mesna]], [[ifosfamide]], [[novantrone]], [[etoposide]] plus [[rituximab]]
| [[Non-Hodgkin's lymphoma]] and [[Hodgkin lymphoma]] in [[relapse]] or [[refractoriness|refractory]] cases
|-
| '''Mini-BEAM''' <ref name="pmid7844600">{{cite journal |author=Colwill R, Crump M, Couture F, ''et al.'' |title=Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation |journal=J. Clin. Oncol. |volume=13 |issue=2 |pages=396–402 |year=1995 |month=February |pmid=7844600 |doi= |url=}}</ref>
| Carmustine (BCNU), etopiside, cytarabine (Ara-C), melphalan
| Hodgkin's lymphoma ([[Salvage therapy]], pre-[[Stem cell transplantation|transplant]])
|-
| '''[[MOPP (medicine)|MOPP]]'''
| [[Mechlorethamine]], [[vincristine]] ([[oncovin]]), [[procarbazine]], [[prednisone]]
| [[Hodgkin's lymphoma]]
|-
| '''MVAC''' <ref name="pmid11001674">{{cite journal |author=von der Maase H, Hansen SW, Roberts JT, ''et al.'' |title=Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study |journal=J. Clin. Oncol. |volume=18 |issue=17 |pages=3068–77 |year=2000 |month=September  pmid=11001674 |doi= |url=}}</ref>
| Methotrexate, vinblastine, doxorubicin, cisplatin
| [[Bladder cancer]]
|-
| '''NABTT''' <ref name="pmid11835382">{{cite journal |author=Herrlinger U, Schabet M, Brugger W, ''et al.'' |title=German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma |journal=Ann. Neurol. |volume=51 |issue=2 |pages=247–52 |year=2002 |month=February |pmid=11835382 |doi= |url=}}</ref>
| Methotrexate, calcium leucovorin; methotrexate, calcium leucovorin; methotrexate, calcium leucovorin
| [[Primary central nervous system lymphoma|Primary CNS lymphoma]]
|-
| '''PCV''' <ref name="pmid7407756">{{cite journal |author=Levin VA, Edwards MS, Wright DC, ''et al.'' |title=Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors |journal=Cancer Treat Rep |volume=64 |issue=2-3 |pages=237–44 |year=1980 |pmid=7407756 |doi= |url=}}</ref>
| [[Procarbazine]], [[lomustine]] (CCNU), [[vincristine]]
| [[Brain tumors]]
|-
| '''ProMACE-MOPP'''
| [[Methotrexate]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]] + [[MOPP (medicine)|MOPP]]
| Non-Hodgkin lymphoma
|-
| '''ProMACE-CytaBOM'''
| [[Prednisone]], [[doxorubicin]] ([[adriamycin]]), [[cyclophosphamide]], [[etoposide]], [[cytarabine]], [[bleomycin]], [[vincristine ]](Oncovin), [[methotrexate]], [[leucovorin]]
| [[Non-Hodgkin lymphoma]]
|-
| '''RdC''' or '''RCD'''
| [[Lenalidomide]] (Revlimid), [[dexamethasone]], [[cyclophosphamide]]
| [[Multiple myeloma]]
|-
| '''R-DHAOx''' <ref name="urlScienceDirect - Biomedicine & Pharmacotherapy : Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect
in previously treated patients with follicular non-Hodgkins lymphoma">{{cite web |url=http://dx.doi.org/10.1016/j.biopha.2009.11.001 |title=ScienceDirect - Biomedicine & Pharmacotherapy : Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma |format= |work= |accessdate=}}</ref>
| Rituximab, dexamethasone, high-dose cytarabine, [[oxaliplatin]]
| Previously treated [[follicular lymphoma]]
|-
| '''R-FCM'''
| [[Rituximab]], [[fludarabine]], [[cyclophosphamide]], [[mitoxantrone]]
| [[B cell]] non-Hodgkin lymphoma
|-
| '''RTOG 93-10''' <ref name="pmid12488408">{{cite journal |author=DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ |title=Combination chemotherapy and radiotherapy for primary central nervous system
| lymphoma: Radiation Therapy Oncology Group Study 93-10 |journal=J. Clin. Oncol. |volume=20 |issue=24 |pages=4643–8 |year=2002 |month=December |pmid=12488408 |doi= |url=}}</ref>
| Methotrexate, Leucovorin, vincristine, procarbazine, methotrexate, Leucovorin
| [[Primary central nervous system lymphoma|Primary CNS lymphoma]]
|-
| '''RVD'''
| [[Lenalidomide]] (Revlimid), [[bortezomib]] (Velcade), [[dexamethasone]]
| [[Multiple myeloma]]
|-
| '''SMILE'''
| Steroid (dexamethasone/prednisolone), methotrexate, ifosfamide, L-asparaganase, etopisode
| Advanced refractory NK/T-cell lymphoma and leukemia 
|-
| '''[[Stanford V]]''' <ref name="pmid7537796">{{cite journal |author=Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ |title=Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report |journal=J. Clin. Oncol. |volume=13 |issue=5 |pages=1080–8 |year=1995 |month=May |pmid=7537796 |doi= |url=}}</ref>
| [[Doxorubicin]] ([[Adriamycin]]), [[mechlorethamine]], [[bleomycin]], vinblastine, vincristine (Oncovin), etoposide ([[VP-16]]), prednisone
| Hodgkin's lymphoma
|-
| '''TAC''' <ref name="pmid11208821">{{cite journal |author=Nabholtz JM, Mackey JR, Smylie M, ''et al.'' |title=Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer |journal=J. Clin. Oncol. |volume=19 |issue=2 |pages=314–21 |year=2001 |month=January |pmid=11208821 |doi= |url=}}</ref>
| Docetaxel, doxorubicin, cyclophosphamide
| Metastatic breast cancer
|-
| '''TAP''' <ref name="pmid15169803">{{cite journal |author=Fleming GF, Brunetto VL, Cella D, ''et al.'' |title=Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study |journal=J. Clin. Oncol. |volume=22 |issue=11 |pages=2159–66 |year=2004 |month=June |pmid=15169803 |doi=10.1200/JCO.2004.07.184 |url=}}</ref>
| Paclitaxel, doxorubicin, cisplatin
| [[Endometrial cancer]]
|-
| '''TCH'''
| [[Paclitaxel]] (Taxol), [[carboplatin]], [[trastuzumab]] (Herceptin)
| [[Breast cancer]] with positive [[HER2/neu]] receptor
|-
| '''Thal/Dex'''
| [[Thalidomide]], dexamethasone
| Multiple myeloma
|-
| '''TIP'''
| [[Paclitaxel]] (Taxol), [[ifosfamide]], platinum agent [[cisplatin|cisplatin (Platinol)]]
| [[Testicular cancer]], [[germ cell tumor]]s in salvage therapy
|-
| '''Treanda + Rituxan'''
| [[Bendamustine]], [[Rituximab]]
| Indolent and [[mantle cell lymphoma|mantle cell lymphomas]]
|-
| '''VAC'''
| [[Vincristine]], [[actinomycin]], [[cyclophosphamide]]
| [[Rhabdomyosarcoma]]
|-
| '''VAD'''
| [[Vincristine]], [[Adriamycin]] (doxorubicin), [[dexamethasone]]
| [[Multiple myeloma]]
|-
| '''VAPEC-B'''
| [[Vincristine]], [[doxorubicin]] (Adriamycin), [[prednisone]], [[etoposide]], [[cyclophosphamide]], [[bleomycin]]
| [[Hodgkin's lymphoma]]
|-
| '''VCAP-AMP-VECP''' <ref name="pmid17968021">{{cite journal |author=Tsukasaki K, Utsunomiya A, Fukuda H, ''et al.'' |title=VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801 |journal=J. Clin. Oncol. |volume=25 |issue=34 |pages=5458–64 |year=2007 |month=December |pmid=17968021 |doi=10.1200/JCO.2007.11.9958 |url=}}</ref>
| Vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP)--doxorubicin, [[ranimustine]], and prednisone (AMP)-- [[vindesine]], etoposide, carboplatin, and prednisone (VECP)
| Adult T-cell leukemia-lymphoma (ATLL)
|-
| '''VeIP''' <ref name="pmid9667270">{{cite journal |author=Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH |title=Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor |journal=J. Clin. Oncol. |volume=16 |issue=7 |pages=2500–4 |year=1998 |month=July |pmid=9667270 |doi= |url=}}</ref>
| Vinblastine, ifosfamide, cisplatin
| [[Testicular cancer]]
|-
| '''VIP''' <ref name="pmid9552027">{{cite journal |author=Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ |title=Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study |journal=J. Clin. Oncol. |volume=16 |issue=4 |pages=1287–93 |year=1998 |month=April |pmid=9552027 |doi= |url=}}</ref>
| Etopiside, ifosfamide, cisplatin
| [[Testicular cancer]]
|-
| '''VTD-PACE'''
| [[Bortezomib]] (Velcade), [[thalidomide]], [[dexamethasone]] plus [[platinum-based antineoplastic|platinum agent]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]]
| [[Multiple myeloma]]
|}


==References==
==References==

Revision as of 14:45, 27 February 2015

WikiDoc Resources for List of chemotherapy regimens

Articles

Most recent articles on List of chemotherapy regimens

Most cited articles on List of chemotherapy regimens

Review articles on List of chemotherapy regimens

Articles on List of chemotherapy regimens in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on List of chemotherapy regimens

Images of List of chemotherapy regimens

Photos of List of chemotherapy regimens

Podcasts & MP3s on List of chemotherapy regimens

Videos on List of chemotherapy regimens

Evidence Based Medicine

Cochrane Collaboration on List of chemotherapy regimens

Bandolier on List of chemotherapy regimens

TRIP on List of chemotherapy regimens

Clinical Trials

Ongoing Trials on List of chemotherapy regimens at Clinical Trials.gov

Trial results on List of chemotherapy regimens

Clinical Trials on List of chemotherapy regimens at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on List of chemotherapy regimens

NICE Guidance on List of chemotherapy regimens

NHS PRODIGY Guidance

FDA on List of chemotherapy regimens

CDC on List of chemotherapy regimens

Books

Books on List of chemotherapy regimens

News

List of chemotherapy regimens in the news

Be alerted to news on List of chemotherapy regimens

News trends on List of chemotherapy regimens

Commentary

Blogs on List of chemotherapy regimens

Definitions

Definitions of List of chemotherapy regimens

Patient Resources / Community

Patient resources on List of chemotherapy regimens

Discussion groups on List of chemotherapy regimens

Patient Handouts on List of chemotherapy regimens

Directions to Hospitals Treating List of chemotherapy regimens

Risk calculators and risk factors for List of chemotherapy regimens

Healthcare Provider Resources

Symptoms of List of chemotherapy regimens

Causes & Risk Factors for List of chemotherapy regimens

Diagnostic studies for List of chemotherapy regimens

Treatment of List of chemotherapy regimens

Continuing Medical Education (CME)

CME Programs on List of chemotherapy regimens

International

List of chemotherapy regimens en Espanol

List of chemotherapy regimens en Francais

Business

List of chemotherapy regimens in the Marketplace

Patents on List of chemotherapy regimens

Experimental / Informatics

List of terms related to List of chemotherapy regimens

Template:Seealso Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ross Bonander

Overview

A chemotherapy regimen is a regimen for chemotherapy defining the drugs to be used, their dosage, the frequency and duration of treatments and other considerations. In modern oncology almost all regimens in use combine several chemotherapy drugs in combination chemotherapy. Acronyms often identify the individual agents used in combination chemotherapy regimens. Unfortunately, the letters used are not consistent across regimens, and in some cases (for example, "BEACOPP") the same letter is used to represent two different treatments. Because of this, there is not a naming standard for chemotherapy regimens, and this page merely represents commonly used conventions.

List of Chemotherapy Regimens

References

External Links

Retrieved from "https://www.wikidoc.org/index.php?title=List_of_chemotherapy_regimens&oldid=1073916"